Background
Section 340B of the Public Health Service Act requires participating drug manufacturers to offer covered outpatient drugs to eligible healthcare providers at or below a statutory ceiling price. Manufacturers historically implemented that price reduction primarily through upfront discounts. HHS has authorized a rebate option for AIDS Drug Assistance Programs, but it has not authorized a broader rebate mechanism covering the models at issue.
In 2024, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, and Novartis proposed models under which covered entities or their contract pharmacies would initially pay full price and later seek refunds equaling the difference between that price and the 340B ceiling price. HRSA told the manufacturers that they could not implement those models without the Secretary’s approval, requested additional information, and indicated that review remained ongoing. The manufacturers and technology company Kalderos sued under the Administrative Procedure Act. The district courts entered summary judgment for the Secretary, and the D.C. Circuit consolidated the appeals.
The Court’s Holding
The D.C. Circuit affirmed. It first rejected the intervening healthcare providers’ contention that Section 340B categorically forbids rebates. The statute expressly contemplates that the amount paid may take into account a “rebate or discount,” and neither its requirement that manufacturers offer drugs at or below the ceiling price nor its auditing provision limits manufacturers exclusively to point-of-purchase discounts.
The court nevertheless held that manufacturers cannot unilaterally impose rebate models. The statutory phrase “any rebate or discount, as provided by the Secretary” requires the Secretary to provide for a permissible pricing mechanism before a manufacturer may use it. That approval need not appear exclusively in a manufacturer’s Pharmaceutical Pricing Agreement. Because the Secretary had never provided for a mechanism encompassing the proposed models, HRSA properly required the manufacturers to await approval while the agency continued reviewing their proposals.
The court rejected the manufacturers’ arbitrary-and-capricious challenge because the preapproval requirement follows from the statute rather than a discretionary change in agency policy. It also held unripe the claim that HHS failed to consider important benefits of the proposals: the agency had said “not yet,” not finally rejected them. The court did not decide whether HHS should approve the proposed models, what restrictions approval might include, or whether any particular model would otherwise comply with Section 340B.
Key Takeaways
- Section 340B permits rebate mechanisms and does not invariably require an upfront discount.
- A manufacturer may not implement a 340B rebate model unless the HHS Secretary has first provided for that type of mechanism.
- The Secretary’s approval authority is not confined to Pharmaceutical Pricing Agreements and may be exercised through other means.
- The decision does not resolve whether HHS should approve the manufacturers’ proposals or whether those proposals satisfy every statutory requirement.
Why It Matters
The ruling preserves HHS’s control over how Section 340B price reductions are delivered while confirming that rebates remain legally available in principle. Drug manufacturers therefore cannot replace existing discount arrangements with their own rebate systems merely by notifying the agency and proceeding unless disapproved.
For covered entities, manufacturers, and contract pharmacies, the immediate consequence is that the proposed full-price-then-refund models remain unavailable without affirmative Secretarial authorization. Future disputes may address the substance of any final HHS decision, including the conditions imposed on a rebate program and its effects on providers and patients.